scRNA and TCR-Seq of peripheral blood mononuclear cells (PBMC)   from r/r classical Hodgkin Lymphoma patients  under anti-PD1 therapy.
We did scRNA and TCR-seq in order to determine the immunophenotic profile of refractory and relapsed patients under anti-PD1 therapy and evaluate based on their response. Overall design: PBMC were  isolated from the blood of each patients. All samples wew  sequenced at 3 different time-point: baseline, post cicle 5  and post cycle 9 of therapy.